These VEGF-targeting agents have been tested in multiple cancer types as single agents or in combination with other therapies (reviewed in (Ferrara & Adamis, 2016; Fukumura et al., 2018; Jain, 2014; Jayson et al., 2016; Khan & Kerbel, 2018; Lee et al., 2020; Zirlik & Duyster, 2018)). The gene discussed is VEGFA; the disease is cancer.